Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

Blood

Volumn 96, Issue 9, 2000, Pages 3102-3108

  Brossart, Peter ^a   Wirths, Stefan ^a   Stuhler, Gernot ^a   Reichardt, Volker L ^a   Kanz, Lothar ^a   Brugger, Wolfram ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE ACTIVATION; TANDEM REPEAT; TARGET CELL; VACCINATION;

EID: 0034331218     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3102.h8003102_3102_3108     Document Type: Article

References (38)

1. Cancer tumor antigens
2. Cancer vaccines
3. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
4. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
5. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
6. Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER-2/-neu derived peptide
7. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
8. HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
9. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats
10. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas
11. Cellular mucins: Targets for immunotherapy
12. MUC1 epithelial tumor-mucin-based immunity and cancer vaccines
13. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
14. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
15. The dendritic cell system and its role in immunogenicity
16. Dendritic cells and the control of immunity
17. Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
18. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
19. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
20. Adenovirus mediated delivery of antigenic epitopes into DC by a means of CTL induction
21. Origin, maturation and antigen presenting function of dendritic cells
22. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumour necrosis factor alpha
23. + dendritic cells
24. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor
25. Dendritic cell vaccines for cancer immunotherapy
26. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
27. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
28. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
29. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
30. T-cell epitope mapping by flow cytometry
31. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
32. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy
33. Expression of MUC-1 epitopes in normal bone marrow: Implications for the detection of micrometastatic tumor cells
34. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self-peptide
35. Cross-priming for a secondary cytotoxic response to minor H-antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
36. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
37. Presentation of exogenous antigens on MHC class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
38. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules